These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
602 related articles for article (PubMed ID: 19506159)
1. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159 [TBL] [Abstract][Full Text] [Related]
2. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Gilbert MR; Wang M; Aldape KD; Stupp R; Hegi ME; Jaeckle KA; Armstrong TS; Wefel JS; Won M; Blumenthal DT; Mahajan A; Schultz CJ; Erridge S; Baumert B; Hopkins KI; Tzuk-Shina T; Brown PD; Chakravarti A; Curran WJ; Mehta MP J Clin Oncol; 2013 Nov; 31(32):4085-91. PubMed ID: 24101040 [TBL] [Abstract][Full Text] [Related]
3. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196 [TBL] [Abstract][Full Text] [Related]
4. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547 [TBL] [Abstract][Full Text] [Related]
5. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989 [TBL] [Abstract][Full Text] [Related]
6. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084 [TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282 [TBL] [Abstract][Full Text] [Related]
8. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Erpolat OP; Akmansu M; Goksel F; Bora H; Yaman E; Büyükberber S Tumori; 2009; 95(2):191-7. PubMed ID: 19579865 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Penas-Prado M; Hess KR; Fisch MJ; Lagrone LW; Groves MD; Levin VA; De Groot JF; Puduvalli VK; Colman H; Volas-Redd G; Giglio P; Conrad CA; Salacz ME; Floyd JD; Loghin ME; Hsu SH; Gonzalez J; Chang EL; Woo SY; Mahajan A; Aldape KD; Yung WK; Gilbert MR; ; Neuro Oncol; 2015 Feb; 17(2):266-73. PubMed ID: 25239666 [TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646 [TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844 [TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
13. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. Grossman SA; Ye X; Chamberlain M; Mikkelsen T; Batchelor T; Desideri S; Piantadosi S; Fisher J; Fine HA J Clin Oncol; 2009 Sep; 27(25):4155-61. PubMed ID: 19636006 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329 [TBL] [Abstract][Full Text] [Related]
15. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182 [TBL] [Abstract][Full Text] [Related]
16. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459 [TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635 [TBL] [Abstract][Full Text] [Related]
20. Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma. Muni R; Minniti G; Lanzetta G; Caporello P; Frati A; Enrici MM; Marchetti P; Enrici RM Tumori; 2010; 96(1):60-4. PubMed ID: 20437859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]